title: Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
abstract: Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2)  every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
authors.affiliation: Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G.Pascale', IRCCS, Naples.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Corazzelli
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Frigeri
authors.forename: Manuela
authors.initials: M
authors.lastname: Arcamone
authors.forename: Luigi
authors.initials: L
authors.lastname: Aloj
authors.forename: Gaetana
authors.initials: G
authors.lastname: Capobianco
authors.forename: Cristina
authors.initials: C
authors.lastname: Becchimanzi
authors.forename: Emanuela
authors.initials: E
authors.lastname: Morelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Volzone
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Marcacci
authors.forename: Filippo
authors.initials: F
authors.lastname: Russo
authors.forename: Rosaria
authors.initials: R
authors.lastname: De Filippi
authors.forename: Secondo
authors.initials: S
authors.lastname: Lastoria
authors.forename: Antonio
authors.initials: A
authors.lastname: Pinto
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine